Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Apitox, purified honeybee toxin, lyophilized in saline · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Apitox, purified honeybee toxin, lyophilized in saline | BIOLOGICAL | intradermal injections of 0.1mg apitox in 0.1ml WFI over 12 weeks treatment period, injections twice weekly range from 1 to 20 injections |
| histamine | BIOLOGICAL | imitates pain and erythema of honeybee venom |
Top 5 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 3 | PHASE3 | Eloralintide and Tirzepatide, Orforglipron, LY3016859, LY3556050, LY3526318 |
| Pacira Biosciences, Inc. | PCRX | 4 | PHASE3 | ZILRETTA, Enekinragene Inzadenovec, FX201 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 1 | PHASE3 | NNC0487-0111 |
| Bioventus, Inc. Class A | BVS | 1 | PHASE2 | PTP-001 |
| Enlivex Ltd. | ENLV | 2 | PHASE1 | Allocetra |
Apitox is being developed for the treatment of osteoarthritis of the knee. It is a purified honeybee toxin formulation that is lyophilized in saline. The drug is intended to address pain and inflammation associated with knee osteoarthritis, a musculoskeletal condition.
Apitox is being developed by Apimeds Pharmaceuticals US, Inc., which trades under the ticker symbol APUS. The company is responsible for the clinical development of this purified honeybee toxin product.
Apitox is in Phase 3 clinical development. The program includes one completed Phase 3 trial, and there are currently no active trials listed. The drug remains investigational and has not been approved by the FDA.
Apitox has been studied in a single Phase 3 clinical trial, NCT01112722, titled "Apitox, Honeybee Toxin for Pain and Inflammation of Osteoarthritis." The trial was completed, enrolled 363 participants, and was conducted in the United States.
Yes, Apitox is also known as purified honeybee toxin, lyophilized in saline. These terms refer to the same investigational product being developed by Apimeds Pharmaceuticals US, Inc. for knee osteoarthritis.